Therapeutic area intelligence for Antiepileptic with 65 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 65
Catalysts: 0
Companies: 21

Companies

Alembic Pharmaceuticals →

Annora Pharma →

Aurobindo Pharma →

Biocon Pharma →

Glenmark Pharmaceuticals →

Hetero Labs →

Invagen Pharmaceuticals →

Sciegen Pharmaceuticals →

Strides Pharma →

Sun Pharma →

Taro →

Torrent Pharmaceuticals →

UMEDICA LABS →

Vertex Pharmaceuticals →

Zydus Pharmaceuticals →

Assets

Recent signals(65)

RegulatoryAugust 6, 2026

FDA Approves Levetiracetam in Sodium Chloride by Mylan Labs

The FDA has approved the application ANDA218364 for levetiracetam in sodium chloride submitted by Mylan Labs.

RegulatoryAugust 5, 2026

FDA Grants AP Status for Carbamazepine ANDA207798 by UMEDICA

The FDA has granted Abbreviated Approval (AP) status for UMEDICA's ANDA207798 for Carbamazepine.

RegulatoryAugust 3, 2026

FDA Approves Lamotrigine Supplement Application by Taro

The FDA has approved a supplemental application for lamotrigine submitted by Taro.

RegulatoryAugust 3, 2026

FDA Grants Approval for Valproic Acid Supplement by Sun Pharma

The FDA has granted approval for the supplemental application ANDA091037 for Valproic Acid submitted by Sun Pharma.

RegulatoryAugust 2, 2026

FDA Grants AP Status for Lamotrigine ANDA078982 by Granules

The FDA has granted approval status (AP) for the ANDA078982 application for Lamotrigine submitted by Granules.

RegulatoryAugust 2, 2026

FDA Acceptance of Lacosamide Supplement by MSN Labs

The FDA has accepted a supplemental application for Lacosamide submitted by MSN Labs.

RegulatoryAugust 1, 2026

FDA Approval Process Update for OXCARBAZEPINE by UMEDICA LABS

UMEDICA LABS has submitted an original application for OXCARBAZEPINE, currently under standard review.

RegulatoryJuly 31, 2026

FDA Approval Status Update for Carbamazepine ANDA205571 by Zydus Pharmaceuticals

The FDA has granted an approval status of 'AP' for ANDA205571, a supplemental application for Carbamazepine by Zydus Pharmaceuticals.

RegulatoryJuly 31, 2026

Aurobindo Pharma submits original application for Cenobamate

Aurobindo Pharma has submitted an original application for Cenobamate under ANDA219473, currently under standard review.

StrategyJuly 30, 2026

FDA Approves Lamotrigine ANDA206382 Submission by Sciegen Pharmaceuticals

The FDA has accepted the Abbreviated New Drug Application (ANDA) for lamotrigine submitted by Sciegen Pharmaceuticals.

StrategyJuly 30, 2026

FDA Grants Approval for Biocon's Topiramate ANDA220943

The FDA has granted approval for Biocon Pharma's Abbreviated New Drug Application (ANDA) for Topiramate.

RegulatoryJuly 28, 2026

FDA Grants AP Status for Levetiracetam Supplement by Strides Pharma

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for a supplement of levetiracetam submitted by Strides Pharma.

RegulatoryJuly 28, 2026

FDA Grants AP Status for Carbamazepine ANDA219072 by Yichang Humanwell

The FDA has granted approval status (AP) for the ANDA219072 application for Carbamazepine submitted by Yichang Humanwell.

RegulatoryJuly 28, 2026

FDA Accepts Lamotrigine Supplement Application from Glenmark

The FDA has accepted a supplemental application for Lamotrigine from Glenmark Pharmaceuticals.

RegulatoryJuly 26, 2026

FDA Approval Process Update for Lamotrigine by Alembic Pharmaceuticals

Alembic Pharmaceuticals has submitted a supplemental application for Lamotrigine, currently under standard review.

StrategyJuly 26, 2026

FDA Grants AP Status for Lamotrigine ANDA078947 by Torrent Pharmaceuticals

The FDA has granted Abbreviated Approval (AP) status for Torrent Pharmaceuticals' ANDA078947 for Lamotrigine.

RegulatoryJuly 25, 2026

FDA Accepts Supplemental NDA for Subvenite (Lamotrigine) by OWP Pharms

The FDA has accepted a supplemental NDA for Subvenite, which contains lamotrigine as the active ingredient.

RegulatoryJuly 22, 2026

FDA Accepts Supplement for Oxcarbazepine ANDA215332

The FDA has accepted a supplemental application for oxcarbazepine under ANDA215332 from sponsor AUCTA.

RegulatoryJuly 21, 2026

FDA Grants Approval for OXCARBAZEPINE ANDA209020

The FDA has granted approval for the ANDA209020 application for OXCARBAZEPINE submitted by MSN.

RegulatoryJuly 21, 2026

FDA Approval Update for OXCARBAZEPINE by Glenmark Pharmaceuticals

The FDA has accepted the supplemental application for OXCARBAZEPINE submitted by Glenmark Pharmaceuticals.

RegulatoryJuly 21, 2026

Lupin's Divalproex Sodium Supplement Receives FDA AP Status

Lupin's application for Divalproex Sodium has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryJuly 21, 2026

FDA Accepts Supplement for OXCARBAZEPINE by Annora Pharma

The FDA has accepted a supplemental application for OXCARBAZEPINE submitted by Annora Pharma.

StrategyJuly 21, 2026

FDA Grants AP Status for Zydus' Oxcarbazepine ANDA211747

The FDA has granted Abbreviated Approval (AP) status for Zydus' ANDA211747 for oxcarbazepine.

StrategyJuly 20, 2026

FDA Grants Approval for Topiramate ANDA220041 by Riconpharma

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 220041 for Topiramate submitted by Riconpharma.

StrategyJuly 20, 2026

Aurobindo Pharma's Lacosamide ANDA209224 Receives AP Status from FDA

The FDA has granted Aurobindo Pharma's ANDA209224 for Lacosamide an Abbreviated Approval (AP) status.

StrategyJuly 20, 2026

Aurobindo Pharma's Lacosamide ANDA204994 Receives AP Status from FDA

Aurobindo Pharma's application for Lacosamide (ANDA204994) has received an Abbreviated Approval (AP) status from the FDA.

StrategyJuly 20, 2026

FDA Approves ANDA for Lacosamide by Steranco Healthcare

The FDA has granted approval for ANDA220366, a generic version of lacosamide, submitted by Steranco Healthcare.

RegulatoryJuly 19, 2026

FDA Acceptance of Divalproex Sodium Supplement by Apotex

The FDA has accepted the supplemental application for Divalproex Sodium submitted by Apotex.

RegulatoryJuly 19, 2026

FDA Grants AP Status for OXCARBAZEPINE ANDA207717 Submission

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for OXCARBAZEPINE submitted by Rubicon Research.

RegulatoryJuly 18, 2026

FDA Approves Supplement for Tegretol (Carbamazepine) by Novartis

The FDA has approved a supplemental application for Tegretol, an antiepileptic drug containing carbamazepine.

StrategyJuly 18, 2026

FDA Grants Approval for Brivaracetam ANDA219766 by Shandong

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 219766 for Brivaracetam submitted by Shandong.

StrategyJuly 18, 2026

FDA grants AP status for Lamotrigine ANDA219677 by Taro

The FDA has granted Abbreviated Approval (AP) status for Taro's Lamotrigine ANDA219677.

RegulatoryJuly 18, 2026

FDA Accepts Supplement for Oxcarbazepine by Kanchan Healthcare

The FDA has accepted a supplemental application for oxcarbazepine submitted by Kanchan Healthcare.

StrategyJuly 17, 2026

FDA Grants Approval for Lamotrigine ANDA077420 by Rising

The FDA has granted approval for ANDA077420, a generic version of Lamotrigine, submitted by Rising.

RegulatoryJuly 17, 2026

FDA Submission Update for OXCARBAZEPINE by Rubicon Research

Rubicon Research has submitted a supplemental application for OXCARBAZEPINE (ANDA077747) with standard review priority.

RegulatoryJuly 15, 2026

FDA Accepts Supplement for Oxcarbazepine by Hetero Labs

The FDA has accepted a supplemental application for oxcarbazepine submitted by Hetero Labs.

RegulatoryJuly 15, 2026

FDA Accepts Supplement for Oxcarbazepine by Chartwell RX

The FDA has accepted a supplemental application for oxcarbazepine submitted by Chartwell RX.

StrategyJuly 14, 2026

FDA Approves Lamotrigine ANDA078625 by Rubicon Research

The FDA has approved ANDA078625 for Lamotrigine submitted by Rubicon Research.

RegulatoryJuly 14, 2026

FDA Grants Approval for Levetiracetam in Sodium Chloride by Mylan Labs

The FDA has granted approval for Mylan Labs' ANDA218364, a formulation of levetiracetam in sodium chloride.

StrategyJuly 13, 2026

FDA Grants AP Status for Lamotrigine ANDA079204 by Taro

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Lamotrigine submitted by Taro.

RegulatoryJuly 12, 2026

FDA Grants AP Status for Valproic Acid ANDA091037 by Sun Pharma

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Valproic Acid submitted by Sun Pharma.

StrategyJuly 11, 2026

Granules' Lamotrigine ANDA078982 Receives Approval Status

Granules has received an Approval Pending (AP) status for their ANDA078982 application for Lamotrigine.

StrategyJuly 11, 2026

FDA Grants AP Status for Zydus' Carbamazepine ANDA205571

The FDA has granted approval status (AP) for Zydus Pharmaceuticals' ANDA205571 for Carbamazepine.

StrategyJuly 9, 2026

FDA Grants Approval for Brivaracetam ANDA219952 by Sciegen Pharmaceuticals

The FDA has granted approval for the Abbreviated New Drug Application (ANDA219952) for Brivaracetam submitted by Sciegen Pharmaceuticals.

RegulatoryJuly 8, 2026

FDA Grants AP Status for Carbamazepine ANDA215591 by Zhejiang Jiuzhou

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Carbamazepine submitted by Zhejiang Jiuzhou.

StrategyJuly 8, 2026

UMEDICA LABS Receives FDA Approval for OXCARBAZEPINE ANDA218341

UMEDICA LABS has received FDA approval for their Abbreviated New Drug Application (ANDA) for OXCARBAZEPINE.

RegulatoryJuly 8, 2026

FDA Accepts Aurobindo's Application for Cenobamate

The FDA has accepted Aurobindo Pharma's application for Cenobamate under ANDA219473.

ClinicalJuly 6, 2026

Vertex Pharmaceuticals Evaluates Suzetrigine's PK with Efavirenz in Healthy Participants

A study is underway to assess the pharmacokinetics and safety of Suzetrigine when co-administered with efavirenz.

RegulatoryJuly 6, 2026

FDA Grants AP Status for Topiramate Supplement by Invagen Pharmaceuticals

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for a supplement of Topiramate submitted by Invagen Pharmaceuticals.

RegulatoryJuly 5, 2026

FDA Grants AP Status for Levetiracetam Supplement by Strides Pharma

The FDA has granted Abbreviated Approval (AP) status for a supplement application of levetiracetam submitted by Strides Pharma.

RegulatoryJuly 4, 2026

FDA Grants AP Status for Carbamazepine ANDA219072 by Yichang Humanwell

The FDA has granted approval status (AP) for the ANDA219072 application for Carbamazepine submitted by Yichang Humanwell.

RegulatoryJuly 4, 2026

FDA Approves Lamotrigine Supplement from Glenmark Pharmaceuticals

The FDA has approved a supplement for Lamotrigine submitted by Glenmark Pharmaceuticals.

RegulatoryJuly 4, 2026

FDA Grants AP Status for Valproic Acid ANDA090517 by Quagen

The FDA has granted Abbreviated Approval (AP) status for Quagen's ANDA090517 for Valproic Acid.

CompetitiveJuly 3, 2026

FDA Approves Lamotrigine Supplement from Alembic Pharmaceuticals

The FDA has approved a supplemental application for Lamotrigine submitted by Alembic Pharmaceuticals.

StrategyJune 23, 2026

Aurobindo Pharma's Divalproex Sodium ANDA202419 Receives AP Status

Aurobindo Pharma's Abbreviated New Drug Application for Divalproex Sodium has received an Approval Pending (AP) status.

RegulatoryJune 21, 2026

FDA Accepts Supplement for Levetiracetam ANDA204754 by Aiping Pharm

The FDA has accepted a supplemental application for ANDA204754, a generic version of levetiracetam, from Aiping Pharm.

CompetitiveJune 19, 2026

Lupin's Divalproex Sodium ANDA209286 Receives Abbreviated Approval

Lupin has received an abbreviated approval for its ANDA209286 application for Divalproex Sodium.

RegulatoryJune 19, 2026

FDA Grants AP Status for Divalproex Sodium ANDA217358 by Mankind Pharma

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Divalproex Sodium submitted by Mankind Pharma.

StrategyJune 18, 2026

FDA Grants Approval for Lacosamide ANDA217596

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 217596 for lacosamide.

CompetitiveJune 18, 2026

FDA Submission Update for Topiramate by Aiping Pharm Inc.

Aiping Pharm Inc. has submitted an application (ANDA078499) for Topiramate with a standard review priority.

StrategyJune 18, 2026

FDA Approval Update for Divalproex Sodium by Mylan

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Divalproex Sodium submitted by Mylan.

StrategyJune 18, 2026

FDA Grants Abbreviated Approval for Divalproex Sodium by Unichem

The FDA has granted an abbreviated approval for Divalproex Sodium under application ANDA214643 submitted by Unichem.

RegulatoryJune 7, 2026

Glenmark Pharmaceuticals submits supplemental application for Lamotrigine

Glenmark Pharmaceuticals has submitted a supplemental application for Lamotrigine under ANDA090169, currently under standard review.

StrategyJune 6, 2026

Aurobindo Pharma's Lamotrigine ANDA Submission Receives AP Status

Aurobindo Pharma's ANDA078956 for Lamotrigine has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryJune 6, 2026

FDA Approves Supplement for Levetiracetam by Chartwell RX

The FDA has approved a supplemental application for levetiracetam submitted by Chartwell RX.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.